Impact of Cognitive Impairment on Quality of Life in Multiple Sclerosis Patients-A Comprehensive Review
- PMID: 38893032
- PMCID: PMC11172944
- DOI: 10.3390/jcm13113321
Impact of Cognitive Impairment on Quality of Life in Multiple Sclerosis Patients-A Comprehensive Review
Abstract
Multiple sclerosis (MS) is characterized by a variety of symptoms that have a major impact on quality of life (QoL) even in early stages. In addition to individual motor, sensory, visual disturbances, and brainstem and sphincter disorders, which are expressed through the widely used Expanded Disability Status Scale (EDSS), other manifestations of MS have a detrimental effect on overall functioning and quality of life, such as cognitive impairment, depression, anxiety, fatigue, and pain. However, when talking about QoL, categorical definitions cannot be used because although the concept is generally understood, it is highly nuanced. Suffering from MS can significantly reduce QoL. Numerous research studies have focused on trying to identify and assess which are the elements that most affect the loss of QoL in MS people. However, in addition to the fact that the measurement of QoL can be subjective, it is very difficult to consider these elements in isolation, as they are interrelated. One such limiting factor of QoL that has been investigated is cognitive impairment (CI). This has been shown to have an impact on the lives of MS people, although the different approaches that have been taken to assess CI have evident limitations.
Keywords: cognitive impairment; disability; multiple sclerosis; neurodegenerative diseases; quality of life.
Conflict of interest statement
This study has no sponsors or incentives, nor did it require funding for its development. Neither the participating investigators nor the hospital center have received any financial compensation. The authors declare that they have no conflicts of interest.
Similar articles
-
Multiple sclerosis and quality of life: The role of cognitive impairment on quality of life in people with multiple sclerosis.Mult Scler Relat Disord. 2023 Nov;79:104966. doi: 10.1016/j.msard.2023.104966. Epub 2023 Sep 3. Mult Scler Relat Disord. 2023. PMID: 37690436
-
Does depression in multiple sclerosis mediate effects of cognitive functioning on quality of life?Qual Life Res. 2022 Feb;31(2):497-506. doi: 10.1007/s11136-021-02927-w. Epub 2021 Jul 6. Qual Life Res. 2022. PMID: 34228241
-
Determinants of quality of life in relapsing-remitting and progressive multiple sclerosis.Mult Scler Relat Disord. 2019 May;30:33-37. doi: 10.1016/j.msard.2019.01.049. Epub 2019 Jan 30. Mult Scler Relat Disord. 2019. PMID: 30735970
-
Efficacy of diet on fatigue, quality of life and disability status in multiple sclerosis patients: rapid review and meta-analysis of randomized controlled trials.BMC Neurol. 2022 Oct 20;22(1):388. doi: 10.1186/s12883-022-02913-w. BMC Neurol. 2022. PMID: 36266639 Free PMC article. Review.
-
Prevalence of depression and anxiety in the different clinical forms of multiple sclerosis and associations with disability: A systematic review and meta-analysis.Brain Behav Immun Health. 2022 Jul 6;24:100484. doi: 10.1016/j.bbih.2022.100484. eCollection 2022 Oct. Brain Behav Immun Health. 2022. PMID: 35856061 Free PMC article. Review.
Cited by
-
The Role of Phytochemicals in Managing Neuropathic Pain: How Much Progress Have We Made?Nutrients. 2024 Dec 16;16(24):4342. doi: 10.3390/nu16244342. Nutrients. 2024. PMID: 39770963 Free PMC article. Review.
-
Exploring the Link Between IL-6 rs1800795 G > C SNP and the Severity of Epstein-Barr Virus-Associated Multiple Sclerosis: Potential Impact on Cognitive Impairment.Mol Neurobiol. 2025 Jul 15. doi: 10.1007/s12035-025-05211-x. Online ahead of print. Mol Neurobiol. 2025. PMID: 40663267
-
Impact of Depression, Fatigue, and Pain on Quality of Life in Slovak Multiple Sclerosis Patients.Med Sci Monit. 2025 Apr 26;31:e947630. doi: 10.12659/MSM.947630. Med Sci Monit. 2025. PMID: 40285337 Free PMC article.
-
Mesenchymal stromal/stem cells from perinatal sources: biological facts, molecular biomarkers, and therapeutic promises.Stem Cell Res Ther. 2025 Mar 7;16(1):127. doi: 10.1186/s13287-025-04254-0. Stem Cell Res Ther. 2025. PMID: 40055783 Free PMC article. Review.
-
Effectiveness of Ocrelizumab on Disease Progression and Disability Status in Multiple Sclerosis Patients: A Two-Year Prospective Cohort Study.J Clin Med. 2025 Jan 16;14(2):553. doi: 10.3390/jcm14020553. J Clin Med. 2025. PMID: 39860559 Free PMC article.
References
-
- Walton C., King R., Rechtman L., Kaye W., Leray E., Marrie R.A., Robertson N., La Rocca N., Uitdehaag B., Van Der Mei I., et al. Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition. Mult. Scler. 2020;26:1816–1821. doi: 10.1177/1352458520970841. - DOI - PMC - PubMed
-
- Logroscino G., Piccininni M., Marin B., Nichols E., Abd-Allah F., Abdelalim A., Alahdab F., Asgedom S.W., Awasthi A., Chaiah Y., et al. Global, regional, and national burden of motor neuron diseases 1990-2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018;17:1083–1097. doi: 10.1016/S1474-4422(18)30404-6. - DOI - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources